Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

719919

Sigma-Aldrich

Resomer® RG 752 H, Poly(D,L-lactide-co-glycolide)

acid terminated, lactide:glycolide 75:25, Mw 4,000-15,000

Synonym(s):

PLGA

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
UNSPSC Code:
12162002
NACRES:
NA.23

form

(Powder or Solid or Chunk(s))

feed ratio

lactide:glycolide 75:25

mol wt

Mw 4,000-15,000

degradation timeframe

<6 months

impurities

≤0.1% Sulfated Ash (CONF0010 Conforms)

viscosity

0.14-0.22 dL/g, 0.5 % in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

transition temp

Tg 42-46 °C

storage temp.

2-8°C

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI key

LCSKNASZPVZHEG-UHFFFAOYSA-N

General description

Poly(D,L-lactide-co-glycolide) (PLGA) is a biodegradable andbioabsorbable polymer that is widely used in the formulation of implantable andinjectable drug delivery systems. PLGA material induces minimal inflammatoryresponse inside the body and degrades to produce biocompatible lactic andglycolic acids.

Legal Information

Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rongcai Liang et al.
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
Shu-Chun Chuang et al.
Parasites & vectors, 6, 34-34 (2013-02-13)
Current development efforts of subunit vaccines against Toxoplasma gondii, the etiological agent of toxoplasmosis, have been focused mainly on tachyzoite surface antigen 1 (SAG1). Since microparticles made from poly (lactide-co-glycolide) (PLG) polymers have been developed as safe, potent adjuvants or
Vanna Sanna et al.
International journal of nanomedicine, 7, 5501-5516 (2012-10-25)
Resveratrol, like other natural polyphenols, is an extremely photosensitive compound with low chemical stability, which limits the therapeutic application of its beneficial effects. The development of innovative formulation strategies, able to overcome physicochemical and pharmacokinetic limitations of this compound, may
Mani Gajendiran et al.
Colloids and surfaces. B, Biointerfaces, 104, 107-115 (2013-01-10)
A series of biodegradable low molecular weight PLGA-PEG-PLGA tri-block copolymers have been synthesized in powder form. The anti-tuberculosis drug Isoniazid (INH) loaded polymeric core-shell nanoparticles (CSNPs) have been prepared by sonication followed by water-in-oil-in-water (w/o/w) double emulsification technique. The nanoparticles
Teresa Musumeci et al.
International journal of pharmaceutics, 440(2), 135-140 (2012-10-20)
Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP). The aim of this study was to generate nanoparticle (NPs) sustained release formulations that allow to extend the pre-corneal residence time of melatonin, thus prolonging

Articles

Interest in utilizing biodegradable polymers for biomedical applications has grown since the 1960s.

Synthetic aliphatic polyesters dominate resorbable biomaterials in clinical use.

AliAliphatic polyesters, including polylactide and polyglycolide, are biodegradable polymers widely used in medical applications.

Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service